APTO - Aptose falls 10% following ASH data on acute myeloid leukemia candidate

Shares of Aptose Biosciences (NASDAQ:APTO) are down 10% in after-hours trading after reporting phase 1/2 data on its acute myeloid leukemia candidate ("AML") HM43239. Results showed that the once-daily, oral myeloid kinome inhibitor showed durable single agent activity in patients with relapsed or refractory acute myeloid leukemia. In the phase 1/2 trial, 34 patients were treated at doses escalating from 20 mg to 160 mg. In a cohort of FLT3 mutant patients treated at 80 mg, three of eight achieved a durable composite complete response. At the same dose, a composite complete response rate of 25% was seen in both FLT3 mutant and FLT3 wild-type AML. Results were presented at the American Society of Hematology Annual Meeting. #ASH2021 Read about the Aptose's license agreement with Hanmi Pharmaceutical for HM43239.

For further details see:

Aptose falls 10% following ASH data on acute myeloid leukemia candidate